- cafead   Dec 06, 2023 at 11:02: AM
via Patients taking Pharvaris’ preventative oral medicine for hereditary angioedema experienced an 84.5% reduction in monthly attacks during a phase 2 study. The results represent a turnaround for the medicine, which until June was on a clinical hold by the FDA.
article source
article source